Inside Oxeia Biopharma’s Mission to Heal Brain Damage From Concussions

On this episode of Inside Startup Investing, Chris Lustrino speaks with Dr. Michael Wyand, CEO of Oxeia Biopharma, a clinical-stage biotech company developing a potential breakthrough treatment for concussions and persistent concussion symptoms. Oxeia is leveraging ghrelin, a naturally occurring hormone involved in brain energy regulation and neural repair, to help heal the inflammation and cellular damage caused by traumatic brain injuries. With promising Phase 2a data showing an 85% responder rate among treated patients, the company is pursuing what could become the first FDA-approved pharmaceutical treatment specifically targeting concussion recovery. Chris and Michael discuss the science behind concussions, how brain damage occurs after impact, why “just rest” has remained the standard of care for decades, and how Oxeia’s therapy could fundamentally change the treatment landscape for athletes, veterans, and millions of patients suffering from lingering neurological symptoms. They also dive into the company’s clinical pathway, the business opportunity behind concussion therapeutics, the role of neurogenesis in recovery, and the broader future potential for treating conditions like CTE, Parkinson’s disease, and ALS. If you want to understand the future of concussion recovery, brain health innovation, and biotech investing, this is an episode you won’t want to miss.